Revolutionizing Glioblastoma Treatment: In Silico Discovery Targets SOX2 Gene through Molecular Docking, Unveiling Potential of Cosmegen and Repurposed Penfluridol

The most severe type of brain tumor resulting from astrocyte malignancy is called a glioblastoma (GBM). Despite numerous developments, the only available treatments are still radiotherapy and chemotherapy, followed by surgery, with a 14–15-month overall survival rate. These treatments have limitations when it comes to improving survival and curing. New treatments targeting GBM based on molecular pathways and pathophysiology are required. As SOX2 interacts with various substrates, it can be utilized as a target here and maybe a desirable target for novel compounds. Through this investigation, we have attempted to categorize different compounds according to their expression and binding efficiency, that can inhibit SOX2 through various pathways. Our investigation revealed that with the help of molecular docking Cosmegen, Penfluridol, and other compounds can inhibit the functioning of SOX2, further resulting in decreased capacity of CSCs (cancer stem cells) to proliferate.